{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:26:41Z","timestamp":1790231201392,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"15","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>HBI0101 is an academic chimeric antigen receptor T-cell (CART)\u2013targeted to B-cell maturation antigen (BCMA) for the treatment of relapsed and refractory multiple myeloma (R\/RMM) and light chain amyloidosis. Herein, we present the phase 1b\/2 results of 50 heavily pretreated patients with R\/RMM dosed with 800\u00a0\u00d7 106 CART cells. Inclusion criteria were relatively permissive (i.e., performance status and baseline organ function) and consequently, approximately half of the enrolled patients would have been ineligible for pivotal clinical trials. The median time elapsed from patient enrollment until CART delivery was 25\u00a0days (range, 14-65). HBI0101-related toxicities included grade 1 to 3 cytokine release syndrome, grade 3 to 4 hematologic toxicities, and grade 1 to 2 immune effector cell\u2013associated neurotoxicity syndrome. Responses were achieved in 90% of the patients, 56% achieved stringent and complete response, and 70% reached a minimal residual disease negativity. Within a median follow-up of 12.3\u00a0months, the median progression-free survival (PFS) was 11.0\u00a0months (95% confidence interval [CI], 6.2-14.6), and the overall survival was not reached (95%\u00a0CI, 13.3 to not reached). Multivariable analysis on patient\/disease and CART-related characteristics revealed that high-risk cytogenetic, extramedullary disease, and increased number of effector-memory T cells in CART products were independently associated with inferior PFS. In conclusion, comprehensive analyses of the parameters affecting the response to CART therapy are essential for improving patients\u2019 outcome. This trial was registered at www.ClinicalTrials.gov as #NCT04720313.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012967","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T20:19:21Z","timestamp":1716236361000},"page":"4077-4088","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed\/refractory multiple myeloma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1475-5960","authenticated-orcid":false,"given":"Shlomit","family":"Kfir-Erenfeld","sequence":"first","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-1208","authenticated-orcid":false,"given":"Nathalie","family":"Asherie","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-7278","authenticated-orcid":false,"given":"Eyal","family":"Lebel","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Vainstein","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miri","family":"Assayag","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3326-4304","authenticated-orcid":false,"given":"Tatyana","family":"Dubnikov Sharon","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-6326","authenticated-orcid":false,"given":"Sigal","family":"Grisariu","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8516-2751","authenticated-orcid":false,"given":"Batia","family":"Avni","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-5317","authenticated-orcid":false,"given":"Shlomo","family":"Elias","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rivka","family":"Alexander-Shani","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nomi","family":"Bessig","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Shehadeh","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"Ishtay","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Zelmanovich","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Zimran","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-2918","authenticated-orcid":false,"given":"Marjorie","family":"Pick","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-4368","authenticated-orcid":false,"given":"Ilan","family":"Roziner","sequence":"additional","affiliation":[{"name":"3Department of Communication Disorders, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-0477","authenticated-orcid":false,"given":"Ron S.","family":"Kenett","sequence":"additional","affiliation":[{"name":"4Kenett-Preminger Associates Ltd, Samuel Neaman Institute, Technion, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Cohen","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Faculty of Medicine, Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Faculty of Medicine, Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0619-5959","authenticated-orcid":false,"given":"Cyrille J.","family":"Cohen","sequence":"additional","affiliation":[{"name":"6Laboratory of Tumor Immunology and Immunotherapy, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-4482","authenticated-orcid":false,"given":"Moshe E.","family":"Gatt","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4923-3660","authenticated-orcid":false,"given":"Polina","family":"Stepensky","sequence":"additional","affiliation":[{"name":"1Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"issue":"9","key":"2024081312510089500_bib1","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"2024081312510089500_bib2","doi-asserted-by":"crossref","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"2024081312510089500_bib3","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"2024081312510089500_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024081312510089500_bib5","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024081312510089500_bib6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10297","key":"2024081312510089500_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"2024081312510089500_bib8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T Cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2024081312510089500_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024081312510089500_bib10","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2021-146210","article-title":"Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)","volume":"138","author":"Dytfeld","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2024081312510089500_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","article-title":"Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience","volume":"29","author":"Kourelis","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2024081312510089500_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40487-023-00228-5","article-title":"Component costs of CAR-T therapy in addition to treatment acquisition costs in patients with multiple myeloma","volume":"11","author":"Jagannath","year":"2023","journal-title":"Oncol Ther"},{"key":"2024081312510089500_bib13","doi-asserted-by":"crossref","first-page":"10732748221142945","DOI":"10.1177\/10732748221142945","article-title":"Cost-effectiveness analysis of CAR T-cell therapies vs antibody drug conjugates for patients with advanced multiple myeloma","volume":"30","author":"Kapinos","year":"2023","journal-title":"Cancer Control"},{"issue":"1","key":"2024081312510089500_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3324\/haematol.2019.228577","article-title":"Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma","volume":"106","author":"Perez-Amill","year":"2021","journal-title":"Haematologica"},{"issue":"8","key":"2024081312510089500_bib15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Caldes","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024081312510089500_bib16","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.3324\/haematol.2021.280169","article-title":"Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma","volume":"107","author":"Harush","year":"2022","journal-title":"Haematologica"},{"issue":"7","key":"2024081312510089500_bib17","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3324\/haematol.2022.281628","article-title":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed\/refractory multiple myeloma: results from a phase I clinical trial","volume":"108","author":"Asherie","year":"2023","journal-title":"Haematologica"},{"issue":"23","key":"2024081312510089500_bib18","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1158\/1078-0432.CCR-22-0637","article-title":"Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis","volume":"28","author":"Kfir-Erenfeld","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2024081312510089500_bib19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","article-title":"Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma","volume":"2","author":"van de Donk","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"2024081312510089500_bib20","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2022.282510","article-title":"Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients","volume":"108","author":"Gagelmann","year":"2023","journal-title":"Haematologica"},{"issue":"14","key":"2024081312510089500_bib21","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"2024081312510089500_bib22","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2024081312510089500_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2024081312510089500_bib24","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"13","key":"2024081312510089500_bib25","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.3390\/cancers15133471","article-title":"Clonal myeloid dysplasia following CAR T-cell therapy: chicken or the egg?","volume":"15","author":"Vainstein","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2024081312510089500_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.clml.2023.01.017","article-title":"SOHO state-of-the-art updates and next questions | BCMA-directed CAR T-cells: early results and future directions","volume":"23","author":"Biltibo","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2024081312510089500_bib27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024081312510089500_bib28","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"2024081312510089500_bib29","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024081312510089500_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"2024081312510089500_bib31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024081312510089500_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T\u00a0memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat Med"},{"issue":"12","key":"2024081312510089500_bib33","doi-asserted-by":"crossref","first-page":"e150807","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2024081312510089500_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bjh.18816","article-title":"Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"202","author":"Dubnikov Sharon","year":"2023","journal-title":"Br J Haematol"},{"issue":"9","key":"2024081312510089500_bib35","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A\u00a0novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov"},{"issue":"19","key":"2024081312510089500_bib36","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"key":"2024081312510089500_bib37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.omtm.2021.12.005","article-title":"Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages","volume":"24","author":"Joedicke","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024081312510089500_bib38","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3389\/fimmu.2020.01217","article-title":"Next-generation manufacturing protocols enriching T(SCM) CAR T cells can overcome disease-specific T cell defects in cancer patients","volume":"11","author":"Arcangeli","year":"2020","journal-title":"Front Immunol"},{"key":"2024081312510089500_bib39","doi-asserted-by":"crossref","first-page":"675179","DOI":"10.3389\/fmolb.2021.675179","article-title":"IL-21 optimizes the CAR-T cell preparation through improving lentivirus mediated transfection efficiency of T cells and enhancing CAR-T cell cytotoxic activities","volume":"8","author":"Du","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2024081312510089500_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.omtm.2022.06.010","article-title":"T\u00a0cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells","volume":"26","author":"Battram","year":"2022","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/4077\/2237847\/blooda_adv-2024-012967-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/4077\/2237847\/blooda_adv-2024-012967-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T12:51:27Z","timestamp":1723553487000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/15\/4077\/516154\/Clinical-evaluation-and-determinants-of-response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":40,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012967","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}